drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00054 | DB06754 | 1,432 | 707 | [
"DDInter6",
"DDInter471"
] | Abciximab | Danaparoid | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity t... | Major | 2 | [
[
[
1432,
25,
707
]
],
[
[
1432,
23,
944
],
[
944,
62,
707
]
],
[
[
1432,
24,
1496
],
[
1496,
63,
707
]
],
[
[
1432,
24,
901
],
[
901,
... | [
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Abciximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Abciximab may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Danaparoid
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may... |
DB01166 | DB01208 | 477 | 945 | [
"DDInter379",
"DDInter1705"
] | Cilostazol | Sparfloxacin | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Major | 2 | [
[
[
477,
25,
945
]
],
[
[
477,
63,
739
],
[
739,
1,
945
]
],
[
[
477,
64,
1176
],
[
1176,
1,
945
]
],
[
[
477,
18,
16896
],
[
16896,
... | [
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lomefl... | Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Cilostazol may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Sparfloxacin (Compound)
Cil... |
DB01211 | DB08931 | 609 | 947 | [
"DDInter393",
"DDInter1600"
] | Clarithromycin | Riociguat | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurre... | Moderate | 1 | [
[
[
609,
24,
947
]
],
[
[
609,
25,
1478
],
[
1478,
24,
947
]
],
[
[
609,
24,
913
],
[
913,
63,
947
]
],
[
[
609,
24,
1344
],
[
1344,
... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivac... | Clarithromycin may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may... |
DB01068 | DB06168 | 1,565 | 1,531 | [
"DDInter411",
"DDInter281"
] | Clonazepam | Canakinumab | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechan... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
1565,
24,
1531
]
],
[
[
1565,
40,
523
],
[
523,
24,
1531
]
],
[
[
1565,
24,
1476
],
[
1476,
63,
1531
]
],
[
[
1565,
24,
1213
],
[
1213... | [
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Clonazepam",
"{u} (Compound) resembles {v} (Compound)",
"Alprazolam"
],
[
"Alprazolam",
"{u} may cause a modera... | Clonazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that coul... |
DB00759 | DB01294 | 1,620 | 266 | [
"DDInter1783",
"DDInter215"
] | Tetracycline | Bismuth subsalicylate | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Bismuth subsalicylate is an antacid and anti-diarrheal agent. Exhibiting antibacterial and gastroprotective properties, bismuth subsalicylate is an insoluble salt of [salicylic acid] linked to trivalent [bismuth cation]. Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. Bismuth s... | Moderate | 1 | [
[
[
1620,
24,
266
]
],
[
[
1620,
6,
1829
],
[
1829,
45,
266
]
],
[
[
1620,
24,
1254
],
[
1254,
63,
266
]
],
[
[
1620,
63,
176
],
[
176,
... | [
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subsalicylate"
]
],
[
[
"Tetracycline",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Co... | Tetracycline (Compound) binds ALB (Gene) and ALB (Gene) is bound by Bismuth subsalicylate (Compound)
Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Bismut... |
DB00491 | DB06595 | 127 | 1,491 | [
"DDInter1217",
"DDInter1214"
] | Miglitol | Midostaurin | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
127,
24,
1491
]
],
[
[
127,
24,
1148
],
[
1148,
24,
1491
]
],
[
[
127,
63,
176
],
[
176,
24,
1491
]
],
[
[
127,
24,
659
],
[
659,
... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and... |
DB00615 | DB09098 | 690 | 98 | [
"DDInter1589",
"DDInter1700"
] | Rifabutin | Somatrem | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
690,
24,
98
]
],
[
[
690,
62,
608
],
[
608,
23,
98
]
],
[
[
690,
64,
168
],
[
168,
23,
98
]
],
[
[
690,
25,
159
],
[
159,
63,
... | [
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Rifabutin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Li... | Rifabutin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Rifabutin may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor in... |
DB06210 | DB12332 | 72 | 1,619 | [
"DDInter631",
"DDInter1626"
] | Eltrombopag | Rucaparib | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
72,
24,
1619
]
],
[
[
72,
63,
1419
],
[
1419,
24,
1619
]
],
[
[
72,
24,
1180
],
[
1180,
63,
1619
]
],
[
[
72,
24,
738
],
[
738,
... | [
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
... | Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant and Rimegepan... |
DB00604 | DB09074 | 1,425 | 1,362 | [
"DDInter385",
"DDInter1327"
] | Cisapride | Olaparib | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
1425,
24,
1362
]
],
[
[
1425,
64,
576
],
[
576,
24,
1362
]
],
[
[
1425,
24,
1478
],
[
1478,
24,
1362
]
],
[
[
1425,
25,
1619
],
[
1619... | [
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methadone"
],
[
"Methadone",
... | Cisapride may lead to a major life threatening interaction when taken with Methadone and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a modera... |
DB00018 | DB01156 | 199 | 593 | [
"DDInter945",
"DDInter252"
] | Interferon alfa-n3 | Bupropion | Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD). | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Major | 2 | [
[
[
199,
25,
593
]
],
[
[
199,
24,
126
],
[
126,
24,
593
]
],
[
[
199,
24,
1383
],
[
1383,
63,
593
]
],
[
[
199,
23,
450
],
[
450,
2... | [
[
[
"Interferon alfa-n3",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Interferon alfa-n3",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
... | Interferon alfa-n3 may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Interferon alfa-n3 may cause a moderate interaction that could exacerbate diseases when taken with Sodium sul... |
DB00748 | DB01233 | 662 | 1,311 | [
"DDInter297",
"DDInter1197"
] | Carbinoxamine | Metoclopramide | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
662,
24,
1311
]
],
[
[
662,
6,
12523
],
[
12523,
45,
1311
]
],
[
[
662,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
662,
63,
1020
],
[
102... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (C... | Carbinoxamine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Metoclopramide (Compound)
Carbinoxamine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB01211 | DB01764 | 609 | 805 | [
"DDInter393",
"DDInter469"
] | Clarithromycin | Dalfopristin | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Moderate | 1 | [
[
[
609,
24,
805
]
],
[
[
609,
6,
8374
],
[
8374,
45,
805
]
],
[
[
609,
62,
222
],
[
222,
23,
805
]
],
[
[
609,
25,
283
],
[
283,
62... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Clarithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (C... | Clarithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dalfopristin (Compound)
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Dalfopristin
Clarithr... |
DB00048 | DB00595 | 1,595 | 1,545 | [
"DDInter435",
"DDInter1374"
] | Collagenase clostridium histolyticum | Oxytetracycline | Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum. It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and Peyronie's disease. The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ... | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | Moderate | 1 | [
[
[
1595,
24,
1545
]
],
[
[
1595,
24,
964
],
[
964,
1,
1545
]
],
[
[
1595,
24,
126
],
[
126,
63,
1545
]
],
[
[
1595,
24,
964
],
[
964,
... | [
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxytetracycline"
]
],
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases... | Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline (Compound) resembles Oxytetracycline (Compound)
Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Warfarin a... |
DB01097 | DB12240 | 1,377 | 110 | [
"DDInter1033",
"DDInter1485"
] | Leflunomide | Polatuzumab vedotin | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Major | 2 | [
[
[
1377,
25,
110
]
],
[
[
1377,
64,
467
],
[
467,
24,
110
]
],
[
[
1377,
25,
980
],
[
980,
24,
110
]
],
[
[
1377,
63,
597
],
[
597,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",... | Leflunomide may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Leflunomide may lead to a major life threatening interaction when taken with Tocilizumab and Tocilizumab may cause ... |
DB08904 | DB11767 | 375 | 1,583 | [
"DDInter342",
"DDInter1643"
] | Certolizumab pegol | Sarilumab | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Major | 2 | [
[
[
375,
25,
1583
]
],
[
[
375,
62,
1461
],
[
1461,
23,
1583
]
],
[
[
375,
23,
1114
],
[
1114,
23,
1583
]
],
[
[
375,
63,
362
],
[
362,
... | [
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
]
],
[
[
"Certolizumab pegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
... | Certolizumab pegol may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Sarilumab
Certolizumab pegol may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate a... |
DB00213 | DB00688 | 837 | 955 | [
"DDInter1388",
"DDInter1251"
] | Pantoprazole | Mycophenolate mofetil | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, ren... | Moderate | 1 | [
[
[
837,
24,
955
]
],
[
[
837,
6,
17404
],
[
17404,
45,
955
]
],
[
[
837,
21,
29233
],
[
29233,
60,
955
]
],
[
[
837,
24,
428
],
[
428,
... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolate mofetil"
]
],
[
[
"Pantoprazole",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v}... | Pantoprazole (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Mycophenolate mofetil (Compound)
Pantoprazole (Compound) causes Creatinine increased (Side Effect) and Creatinine increased (Side Effect) is caused by Mycophenolate mofetil (Compound)
Pantoprazole may cause a moderate interaction that could exacerb... |
DB06791 | DB11757 | 1,446 | 960 | [
"DDInter1021",
"DDInter994"
] | Lanreotide | Istradefylline | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly in... | Moderate | 1 | [
[
[
1446,
24,
960
]
],
[
[
1446,
24,
971
],
[
971,
63,
960
]
],
[
[
1446,
24,
351
],
[
351,
24,
960
]
],
[
[
1446,
24,
971
],
[
971,
... | [
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
... | Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib an... |
DB09074 | DB12332 | 1,362 | 1,619 | [
"DDInter1327",
"DDInter1626"
] | Olaparib | Rucaparib | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1362,
24,
1619
]
],
[
[
1362,
64,
307
],
[
307,
23,
1619
]
],
[
[
1362,
63,
259
],
[
259,
24,
1619
]
],
[
[
1362,
24,
151
],
[
151,
... | [
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Modafinil"
],
[
"Modafinil",
... | Olaparib may lead to a major life threatening interaction when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderat... |
DB00641 | DB15093 | 467 | 1,654 | [
"DDInter1675",
"DDInter1698"
] | Simvastatin | Somapacitan | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
467,
24,
1654
]
],
[
[
467,
63,
168
],
[
168,
23,
1654
]
],
[
[
467,
63,
10
],
[
10,
24,
1654
]
],
[
[
467,
24,
351
],
[
351,
24... | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[... | Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone ... |
DB00427 | DB00557 | 1,233 | 252 | [
"DDInter1879",
"DDInter895"
] | Triprolidine | Hydroxyzine | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Moderate | 1 | [
[
[
1233,
24,
252
]
],
[
[
1233,
24,
851
],
[
851,
1,
252
]
],
[
[
1233,
1,
11268
],
[
11268,
1,
252
]
],
[
[
1233,
24,
623
],
[
623,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
],
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone (Compound) resembles Hydroxyzine (Compound)
Triprolidine (Compound) resembles Cloperastine (Compound) and Cloperastine (Compound) resembles Hydroxyzine (Compound)
Triprolidine may cause a moderate inte... |
DB01320 | DB06674 | 651 | 908 | [
"DDInter783",
"DDInter837"
] | Fosphenytoin | Golimumab | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Moderate | 1 | [
[
[
651,
24,
908
]
],
[
[
651,
63,
458
],
[
458,
24,
908
]
],
[
[
651,
24,
1487
],
[
1487,
24,
908
]
],
[
[
651,
40,
362
],
[
362,
2... | [
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinidazole"
],
[... | Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole and Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine... |
DB00332 | DB00372 | 1,089 | 999 | [
"DDInter970",
"DDInter1793"
] | Ipratropium | Thiethylperazine | Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its... | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Moderate | 1 | [
[
[
1089,
24,
999
]
],
[
[
1089,
63,
352
],
[
352,
24,
999
]
],
[
[
1089,
24,
100
],
[
100,
63,
999
]
],
[
[
1089,
40,
1177
],
[
1177,
... | [
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
... | Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine a... |
DB00728 | DB00741 | 1,610 | 167 | [
"DDInter1612",
"DDInter885"
] | Rocuronium | Hydrocortisone | Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechan... | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
1610,
24,
167
]
],
[
[
1610,
24,
1220
],
[
1220,
40,
167
]
],
[
[
1610,
63,
175
],
[
175,
40,
167
]
],
[
[
1610,
63,
870
],
[
870,
... | [
[
[
"Rocuronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Rocuronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Rocuronium may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Rocuronium may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Hydroc... |
DB00934 | DB06176 | 413 | 1,342 | [
"DDInter1124",
"DDInter1616"
] | Maprotiline | Romidepsin | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does n... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
413,
24,
1342
]
],
[
[
413,
62,
112
],
[
112,
23,
1342
]
],
[
[
413,
63,
485
],
[
485,
24,
1342
]
],
[
[
413,
24,
1520
],
[
1520,
... | [
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Maprotiline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Maprotiline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and P... |
DB00377 | DB00927 | 1,494 | 1,559 | [
"DDInter1382",
"DDInter712"
] | Palonosetron | Famotidine | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Moderate | 1 | [
[
[
1494,
24,
1559
]
],
[
[
1494,
21,
28729
],
[
28729,
60,
1559
]
],
[
[
1494,
23,
1247
],
[
1247,
62,
1559
]
],
[
[
1494,
25,
109
],
[
1... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Palonosetron",
"{u} (Compound) causes {v} (Side Effect)",
"Pain in extremity"
],
[
"Pain in extremity",
"{u} (... | Palonosetron (Compound) causes Pain in extremity (Side Effect) and Pain in extremity (Side Effect) is caused by Famotidine (Compound)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical eff... |
DB06589 | DB08908 | 1,250 | 713 | [
"DDInter1400",
"DDInter564"
] | Pazopanib | Dimethyl fumarate | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Moderate | 1 | [
[
[
1250,
24,
713
]
],
[
[
1250,
25,
996
],
[
996,
24,
713
]
],
[
[
1250,
63,
4
],
[
4,
24,
713
]
],
[
[
1250,
24,
594
],
[
594,
24,... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
],
[
"Beda... | Pazopanib may lead to a major life threatening interaction when taken with Bedaquiline and Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and... |
DB00421 | DB00586 | 443 | 1,512 | [
"DDInter1707",
"DDInter537"
] | Spironolactone | Diclofenac | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Moderate | 1 | [
[
[
443,
24,
1512
]
],
[
[
443,
6,
3486
],
[
3486,
45,
1512
]
],
[
[
443,
21,
28997
],
[
28997,
60,
1512
]
],
[
[
443,
24,
885
],
[
885,
... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]
],
[
[
"Spironolactone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Com... | Spironolactone (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Diclofenac (Compound)
Spironolactone (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Diclofenac (Compound)
Spironolactone may cause a moderate interaction that could exacerbate diseases w... |
DB00196 | DB06589 | 600 | 1,250 | [
"DDInter743",
"DDInter1400"
] | Fluconazole | Pazopanib | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
600,
24,
1250
]
],
[
[
600,
6,
4973
],
[
4973,
45,
1250
]
],
[
[
600,
54,
19146
],
[
19146,
15,
1250
]
],
[
[
600,
21,
29203
],
[
2920... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Fluconazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Pazopanib (Compound)
Fluconazole (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Pazopanib (Compound)
Fluconazole (Compound) causes Aspartate aminotrans... |
DB00086 | DB06209 | 1,167 | 256 | [
"DDInter1712",
"DDInter1508"
] | Streptokinase | Prasugrel | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Major | 2 | [
[
[
1167,
25,
256
]
],
[
[
1167,
23,
944
],
[
944,
62,
256
]
],
[
[
1167,
24,
901
],
[
901,
24,
256
]
],
[
[
1167,
24,
1427
],
[
1427,
... | [
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Streptokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomil... | Streptokinase may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnac... |
DB00607 | DB12001 | 1,249 | 564 | [
"DDInter1256",
"DDInter7"
] | Nafcillin | Abemaciclib | A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be u... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Moderate | 1 | [
[
[
1249,
24,
564
]
],
[
[
1249,
24,
868
],
[
868,
24,
564
]
],
[
[
1249,
25,
1017
],
[
1017,
63,
564
]
],
[
[
1249,
64,
663
],
[
663,
... | [
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
... | Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Nafcillin may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause... |
DB00889 | DB11901 | 1,133 | 913 | [
"DDInter840",
"DDInter107"
] | Granisetron | Apalutamide | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
1133,
24,
913
]
],
[
[
1133,
23,
112
],
[
112,
23,
913
]
],
[
[
1133,
64,
1322
],
[
1322,
24,
913
]
],
[
[
1133,
63,
600
],
[
600,
... | [
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Granisetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Granisetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Granisetron may lead to a major life threatening interaction when taken with Alfentanil and Alfentanil may c... |
DB00603 | DB11569 | 303 | 1,093 | [
"DDInter1137",
"DDInter1003"
] | Medroxyprogesterone acetate | Ixekizumab | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Moderate | 1 | [
[
[
303,
24,
1093
]
],
[
[
303,
24,
1683
],
[
1683,
24,
1093
]
],
[
[
303,
63,
1236
],
[
1236,
24,
1093
]
],
[
[
303,
23,
700
],
[
700,
... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases w... |
DB00647 | DB00816 | 675 | 1,674 | [
"DDInter528",
"DDInter1346"
] | Dextropropoxyphene | Orciprenaline | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Moderate | 1 | [
[
[
675,
24,
1674
]
],
[
[
675,
21,
28921
],
[
28921,
60,
1674
]
],
[
[
675,
40,
1164
],
[
1164,
24,
1674
]
],
[
[
675,
63,
1685
],
[
1685... | [
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
]
],
[
[
"Dextropropoxyphene",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (S... | Dextropropoxyphene (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Orciprenaline (Compound)
Dextropropoxyphene (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Dextropropoxyphene... |
DB00333 | DB11718 | 576 | 927 | [
"DDInter1166",
"DDInter640"
] | Methadone | Encorafenib | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
576,
25,
927
]
],
[
[
576,
23,
112
],
[
112,
23,
927
]
],
[
[
576,
24,
720
],
[
720,
24,
927
]
],
[
[
576,
63,
1324
],
[
1324,
2... | [
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Methadone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Methadone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Methadone may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mine... |
DB00641 | DB09048 | 467 | 555 | [
"DDInter1675",
"DDInter1284"
] | Simvastatin | Netupitant | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug i... | Moderate | 1 | [
[
[
467,
24,
555
]
],
[
[
467,
63,
1101
],
[
1101,
23,
555
]
],
[
[
467,
24,
466
],
[
466,
62,
555
]
],
[
[
467,
25,
384
],
[
384,
6... | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Netupitant
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Daro... |
DB08868 | DB12245 | 1,011 | 823 | [
"DDInter737",
"DDInter1863"
] | Fingolimod | Triclabendazole | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Major | 2 | [
[
[
1011,
25,
823
]
],
[
[
1011,
62,
1247
],
[
1247,
23,
823
]
],
[
[
1011,
25,
1612
],
[
1612,
24,
823
]
],
[
[
1011,
64,
1010
],
[
1010,... | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Fingolimod",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"S... | Fingolimod may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Fingolimod may lead to a major life threatening interaction when taken with Fostemsavir and Fostems... |
DB11799 | DB14568 | 627 | 982 | [
"DDInter205",
"DDInter1000"
] | Bictegravir | Ivosidenib | Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
627,
24,
982
]
],
[
[
627,
63,
1101
],
[
1101,
23,
982
]
],
[
[
627,
63,
1478
],
[
1478,
24,
982
]
],
[
[
627,
64,
286
],
[
286,
... | [
[
[
"Bictegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Bictegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Bictegravir may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Bictegravir may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaft... |
DB01124 | DB12130 | 1,411 | 1,017 | [
"DDInter1828",
"DDInter1094"
] | Tolbutamide | Lorlatinib | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1411,
24,
1017
]
],
[
[
1411,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
1411,
63,
175
],
[
175,
24,
1017
]
],
[
[
1411,
24,
1491
],
[
1491... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Tri... |
DB00673 | DB09381 | 723 | 192 | [
"DDInter112",
"DDInter678"
] | Aprepitant | Esterified estrogens | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of me... | Moderate | 1 | [
[
[
723,
24,
192
]
],
[
[
723,
63,
752
],
[
752,
23,
192
]
],
[
[
723,
25,
1019
],
[
1019,
63,
192
]
],
[
[
723,
63,
1051
],
[
1051,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Esterified estrogens
Aprepitant may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort ... |
DB09049 | DB09065 | 1,135 | 760 | [
"DDInter1261",
"DDInter424"
] | Naloxegol | Cobicistat | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
1135,
25,
760
]
],
[
[
1135,
63,
1101
],
[
1101,
23,
760
]
],
[
[
1135,
62,
1374
],
[
1374,
23,
760
]
],
[
[
1135,
64,
555
],
[
555,
... | [
[
[
"Naloxegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",... | Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Naloxegol may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone... |
DB00222 | DB04946 | 245 | 924 | [
"DDInter825",
"DDInter907"
] | Glimepiride | Iloperidone | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Moderate | 1 | [
[
[
245,
24,
924
]
],
[
[
245,
24,
1664
],
[
1664,
1,
924
]
],
[
[
245,
24,
519
],
[
519,
40,
924
]
],
[
[
245,
21,
28809
],
[
28809,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles Iloperidone (... |
DB04868 | DB06403 | 478 | 1,204 | [
"DDInter1293",
"DDInter62"
] | Nilotinib | Ambrisentan | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the Un... | Moderate | 1 | [
[
[
478,
24,
1204
]
],
[
[
478,
64,
600
],
[
600,
23,
1204
]
],
[
[
478,
25,
760
],
[
760,
62,
1204
]
],
[
[
478,
63,
86
],
[
86,
23... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ambrisentan"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazol... | Nilotinib may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Ambrisentan
Nilotinib may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a minor interact... |
DB00619 | DB01073 | 1,419 | 1,488 | [
"DDInter909",
"DDInter745"
] | Imatinib | Fludarabine | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Moderate | 1 | [
[
[
1419,
24,
1488
]
],
[
[
1419,
24,
372
],
[
372,
1,
1488
]
],
[
[
1419,
5,
11555
],
[
11555,
44,
1488
]
],
[
[
1419,
21,
28701
],
[
287... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine (Compound) resembles Fludarabine (Compound)
Imatinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Fludarabine (Compound)
Imatinib (Compound) causes Discom... |
DB00047 | DB00777 | 176 | 146 | [
"DDInter932",
"DDInter1537"
] | Insulin glargine | Propiomazine | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Struct... | Moderate | 1 | [
[
[
176,
24,
146
]
],
[
[
176,
24,
508
],
[
508,
1,
146
]
],
[
[
176,
24,
401
],
[
401,
63,
146
]
],
[
[
176,
24,
104
],
[
104,
40,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Propiomazine (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate intera... |
DB06702 | DB11901 | 573 | 913 | [
"DDInter731",
"DDInter107"
] | Fesoterodine | Apalutamide | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
573,
24,
913
]
],
[
[
573,
63,
600
],
[
600,
24,
913
]
],
[
[
573,
64,
609
],
[
609,
24,
913
]
],
[
[
573,
24,
1320
],
[
1320,
6... | [
[
[
"Fesoterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Fesoterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
... | Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Fesoterodine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithrom... |
DB11828 | DB14975 | 1,406 | 988 | [
"DDInter1281",
"DDInter1949"
] | Neratinib | Voxelotor | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Major | 2 | [
[
[
1406,
25,
988
]
],
[
[
1406,
63,
629
],
[
629,
24,
988
]
],
[
[
1406,
24,
971
],
[
971,
24,
988
]
],
[
[
1406,
64,
723
],
[
723,
... | [
[
[
"Neratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Voxelotor"
]
],
[
[
"Neratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
... | Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteriti... |
DB00008 | DB12834 | 491 | 148 | [
"DDInter1407",
"DDInter1649"
] | Peginterferon alfa-2a | Secnidazole | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive ... | Moderate | 1 | [
[
[
491,
24,
148
]
],
[
[
491,
24,
1593
],
[
1593,
24,
148
]
],
[
[
491,
25,
1477
],
[
1477,
24,
148
]
],
[
[
491,
63,
1057
],
[
1057,
... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Criz... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Telbivudine a... |
DB00708 | DB08816 | 1,454 | 578 | [
"DDInter1718",
"DDInter1802"
] | Sufentanil | Ticagrelor | Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to w... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
1454,
24,
578
]
],
[
[
1454,
6,
8374
],
[
8374,
45,
578
]
],
[
[
1454,
21,
28762
],
[
28762,
60,
578
]
],
[
[
1454,
63,
723
],
[
723,
... | [
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Sufentanil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Sufentanil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Sufentanil (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ticagrelor (Compound)
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepi... |
DB01030 | DB09498 | 869 | 810 | [
"DDInter1835",
"DDInter1715"
] | Topotecan | Strontium chloride Sr-89 | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
869,
24,
810
]
],
[
[
869,
63,
552
],
[
552,
24,
810
]
],
[
[
869,
64,
1555
],
[
1555,
24,
810
]
],
[
[
869,
24,
689
],
[
689,
6... | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
... | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Topotecan may lead to a major life threatening interaction when taken with Oxaliplatin and Oxalipla... |
DB00307 | DB08899 | 1,101 | 129 | [
"DDInter202",
"DDInter649"
] | Bexarotene | Enzalutamide | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1101,
24,
129
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
129
]
],
[
[
1101,
21,
28703
],
[
28703,
60,
129
]
],
[
[
1101,
23,
271
],
[
271,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Bexarotene (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mira... |
DB00773 | DB14975 | 896 | 988 | [
"DDInter702",
"DDInter1949"
] | Etoposide | Voxelotor | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Moderate | 1 | [
[
[
896,
24,
988
]
],
[
[
896,
24,
629
],
[
629,
24,
988
]
],
[
[
896,
74,
63
],
[
63,
24,
988
]
],
[
[
896,
63,
126
],
[
126,
24,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Etoposide (Compound) resembles Teniposide (Compound) and Etoposide may cause a moderate interaction that could exace... |
DB08908 | DB11988 | 713 | 270 | [
"DDInter564",
"DDInter1321"
] | Dimethyl fumarate | Ocrelizumab | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
713,
24,
270
]
],
[
[
713,
24,
1060
],
[
1060,
63,
270
]
],
[
[
713,
63,
134
],
[
134,
24,
270
]
],
[
[
713,
24,
1019
],
[
1019,
... | [
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab v... | Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when t... |
DB00401 | DB08816 | 84 | 578 | [
"DDInter1298",
"DDInter1802"
] | Nisoldipine | Ticagrelor | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Minor | 0 | [
[
[
84,
23,
578
]
],
[
[
84,
6,
4973
],
[
4973,
45,
578
]
],
[
[
84,
21,
28645
],
[
28645,
60,
578
]
],
[
[
84,
1,
336
],
[
336,
23,... | [
[
[
"Nisoldipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Nisoldipine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Nisoldipine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ticagrelor (Compound)
Nisoldipine (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Ticagrelor (Compound)
Nisoldipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a minor interaction that can limit cli... |
DB00099 | DB00853 | 440 | 1,686 | [
"DDInter735",
"DDInter1762"
] | Filgrastim | Temozolomide | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Moderate | 1 | [
[
[
440,
24,
1686
]
],
[
[
440,
24,
970
],
[
970,
24,
1686
]
],
[
[
440,
24,
1330
],
[
1330,
63,
1686
]
],
[
[
440,
63,
599
],
[
599,
... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temozolomide"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
],
... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil and Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab and N... |
DB00726 | DB01105 | 1,164 | 222 | [
"DDInter1876",
"DDInter1665"
] | Trimipramine | Sibutramine | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Major | 2 | [
[
[
1164,
25,
222
]
],
[
[
1164,
6,
8374
],
[
8374,
45,
222
]
],
[
[
1164,
21,
28698
],
[
28698,
60,
222
]
],
[
[
1164,
63,
600
],
[
600,
... | [
[
[
"Trimipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
]
],
[
[
"Trimipramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Si... | Trimipramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Trimipramine (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Sibutramine (Compound)
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole a... |
DB00696 | DB06663 | 826 | 1,154 | [
"DDInter665",
"DDInter1398"
] | Ergotamine | Pasireotide | A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders. | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
826,
24,
1154
]
],
[
[
826,
63,
966
],
[
966,
40,
1154
]
],
[
[
826,
21,
29024
],
[
29024,
60,
1154
]
],
[
[
826,
24,
1017
],
[
1017,
... | [
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
... | Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide (Compound) resembles Pasireotide (Compound)
Ergotamine (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Pasireotide (Compound)
Ergotamine may cause a moderate inte... |
DB00836 | DB09128 | 543 | 1,241 | [
"DDInter1088",
"DDInter231"
] | Loperamide | Brexpiprazole | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Moderate | 1 | [
[
[
543,
24,
1241
]
],
[
[
543,
24,
129
],
[
129,
24,
1241
]
],
[
[
543,
24,
741
],
[
741,
63,
1241
]
],
[
[
543,
63,
832
],
[
832,
... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and... |
DB00701 | DB09082 | 1,091 | 659 | [
"DDInter90",
"DDInter1934"
] | Amprenavir | Vilanterol | Amprenavir is a protease inhibitor used to treat HIV infection. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
1091,
24,
659
]
],
[
[
1091,
24,
1220
],
[
1220,
23,
659
]
],
[
[
1091,
63,
1351
],
[
1351,
23,
659
]
],
[
[
1091,
64,
175
],
[
175,
... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[... | Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Flunisolide and F... |
DB04835 | DB08901 | 1,655 | 1,468 | [
"DDInter1125",
"DDInter1492"
] | Maraviroc | Ponatinib | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
1655,
24,
1468
]
],
[
[
1655,
24,
478
],
[
478,
24,
1468
]
],
[
[
1655,
6,
8374
],
[
8374,
45,
1468
]
],
[
[
1655,
21,
29425
],
[
2942... | [
[
[
"Maraviroc",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Maraviroc",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Maraviroc (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ponatinib (Compound)
Maraviroc (Compound) cau... |
DB01006 | DB11952 | 300 | 800 | [
"DDInter1040",
"DDInter612"
] | Letrozole | Duvelisib | Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
300,
24,
800
]
],
[
[
300,
24,
1476
],
[
1476,
63,
800
]
],
[
[
300,
24,
1213
],
[
1213,
24,
800
]
],
[
[
300,
63,
723
],
[
723,
... | [
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib ... |
DB06168 | DB06688 | 1,531 | 1,430 | [
"DDInter281",
"DDInter1677"
] | Canakinumab | Sipuleucel-T | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
1531,
24,
1430
]
],
[
[
1531,
63,
175
],
[
175,
24,
1430
]
],
[
[
1531,
25,
676
],
[
676,
63,
1430
]
],
[
[
1531,
24,
310
],
[
310,
... | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
... | Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Canakinumab may lead to a major life threatening interaction when taken with Upadacitinib and Upadaciti... |
DB00970 | DB06168 | 0 | 1,531 | [
"DDInter466",
"DDInter281"
] | Dactinomycin | Canakinumab | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also d... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
0,
24,
1531
]
],
[
[
0,
63,
1461
],
[
1461,
23,
1531
]
],
[
[
0,
63,
377
],
[
377,
24,
1531
]
],
[
[
0,
24,
1270
],
[
1270,
63,
... | [
[
[
"Dactinomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Dactinomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
... | Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab
Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomy... |
DB00802 | DB09065 | 1,322 | 760 | [
"DDInter43",
"DDInter424"
] | Alfentanil | Cobicistat | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
1322,
25,
760
]
],
[
[
1322,
63,
1101
],
[
1101,
23,
760
]
],
[
[
1322,
64,
723
],
[
723,
24,
760
]
],
[
[
1322,
24,
868
],
[
868,
... | [
[
[
"Alfentanil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene... | Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Alfentanil may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant may cause a ... |
DB00561 | DB06707 | 1,048 | 584 | [
"DDInter591",
"DDInter1060"
] | Doxapram | Levonordefrin | A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225) | Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry. | Moderate | 1 | [
[
[
1048,
24,
584
]
],
[
[
1048,
24,
817
],
[
817,
40,
584
]
],
[
[
1048,
24,
1148
],
[
1148,
24,
584
]
],
[
[
1048,
24,
1240
],
[
1240,
... | [
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonordefrin"
]
],
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
],
[
... | Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Dopamine and Dopamine (Compound) resembles Levonordefrin (Compound)
Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could ... |
DB00331 | DB12141 | 1,645 | 971 | [
"DDInter1164",
"DDInter817"
] | Metformin | Gilteritinib | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
1645,
24,
971
]
],
[
[
1645,
24,
485
],
[
485,
24,
971
]
],
[
[
1645,
24,
1654
],
[
1654,
63,
971
]
],
[
[
1645,
63,
966
],
[
966,
... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Som... |
DB00726 | DB01168 | 1,164 | 1,053 | [
"DDInter1876",
"DDInter1526"
] | Trimipramine | Procarbazine | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
1164,
25,
1053
]
],
[
[
1164,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
1164,
63,
126
],
[
126,
23,
1053
]
],
[
[
1164,
24,
480
],
[
480... | [
[
[
"Trimipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Trimipramine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (... | Trimipramine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Procarbaz... |
DB09330 | DB14975 | 985 | 988 | [
"DDInter1352",
"DDInter1949"
] | Osimertinib | Voxelotor | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Moderate | 1 | [
[
[
985,
24,
988
]
],
[
[
985,
24,
466
],
[
466,
23,
988
]
],
[
[
985,
63,
629
],
[
629,
24,
988
]
],
[
[
985,
24,
564
],
[
564,
24,... | [
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[... | Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Voxelotor
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Siro... |
DB00798 | DB01172 | 1,132 | 416 | [
"DDInter815",
"DDInter1004"
] | Gentamicin | Kanamycin | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negat... | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Moderate | 1 | [
[
[
1132,
35,
416
]
],
[
[
1132,
40,
138
],
[
138,
1,
416
]
],
[
[
1132,
54,
19175
],
[
19175,
15,
416
]
],
[
[
1132,
21,
31264
],
[
31264... | [
[
[
"Gentamicin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Gentamicin",
"{u} (Compound) resembles {v} (Compound)",
"Tobramycin"
],
[
"... | Gentamicin (Compound) resembles Kanamycin (Compound) and
Gentamicin (Compound) resembles Tobramycin (Compound) and Tobramycin (Compound) resembles Kanamycin (Compound)
Gentamicin (Compound) is included by Aminoglycosides (Pharmacologic Class) and Aminoglycosides (Pharmacologic Class) includes Kanamycin (Compound)
Genta... |
DB01394 | DB08820 | 1,554 | 1,478 | [
"DDInter431",
"DDInter997"
] | Colchicine | Ivacaftor | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Major | 2 | [
[
[
1554,
25,
1478
]
],
[
[
1554,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
1554,
54,
19146
],
[
19146,
15,
1478
]
],
[
[
1554,
21,
28762
],
[
... | [
[
[
"Colchicine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
]
],
[
[
"Colchicine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ivacafto... | Colchicine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Colchicine (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Ivacaftor (Compound)
Colchicine (Compound) causes Headache (Side Effect... |
DB00773 | DB11952 | 896 | 800 | [
"DDInter702",
"DDInter612"
] | Etoposide | Duvelisib | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
896,
24,
800
]
],
[
[
896,
24,
310
],
[
310,
24,
800
]
],
[
[
896,
63,
467
],
[
467,
24,
800
]
],
[
[
896,
24,
1476
],
[
1476,
6... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvas... |
DB00795 | DB01067 | 50 | 959 | [
"DDInter1725",
"DDInter826"
] | Sulfasalazine | Glipizide | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
50,
24,
959
]
],
[
[
50,
63,
245
],
[
245,
40,
959
]
],
[
[
50,
24,
1411
],
[
1411,
1,
959
]
],
[
[
50,
6,
4789
],
[
4789,
45,
... | [
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Co... |
DB00289 | DB01169 | 847 | 57 | [
"DDInter132",
"DDInter120"
] | Atomoxetine | Arsenic trioxide | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Major | 2 | [
[
[
847,
25,
57
]
],
[
[
847,
6,
8374
],
[
8374,
45,
57
]
],
[
[
847,
23,
112
],
[
112,
23,
57
]
],
[
[
847,
24,
603
],
[
603,
63,
... | [
[
[
"Atomoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Atomoxetine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Atomoxetine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Arsenic trioxide (Compound)
Atomoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Arsenic trioxide
At... |
DB01030 | DB10316 | 869 | 334 | [
"DDInter1835",
"DDInter1248"
] | Topotecan | Mumps virus strain B level jeryl lynn live antigen | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
869,
25,
334
]
],
[
[
869,
24,
594
],
[
594,
25,
334
]
],
[
[
869,
64,
1057
],
[
1057,
25,
334
]
],
[
[
869,
25,
908
],
[
908,
2... | [
[
[
"Topotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosu... | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Topotecan may lead to a major life threatening interaction when taken with Etanercept and ... |
DB00026 | DB06810 | 1,184 | 397 | [
"DDInter94",
"DDInter1484"
] | Anakinra | Plicamycin | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. | Moderate | 1 | [
[
[
1184,
24,
397
]
],
[
[
1184,
24,
151
],
[
151,
63,
397
]
],
[
[
1184,
24,
1430
],
[
1430,
24,
397
]
],
[
[
1184,
23,
1461
],
[
1461,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plicamycin"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) and Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) may cause a moderate interaction that could exacerbate ... |
DB00526 | DB05812 | 1,555 | 1,374 | [
"DDInter1355",
"DDInter8"
] | Oxaliplatin | Abiraterone | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
1555,
24,
1374
]
],
[
[
1555,
24,
112
],
[
112,
23,
1374
]
],
[
[
1555,
23,
1247
],
[
1247,
23,
1374
]
],
[
[
1555,
24,
1399
],
[
1399... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Oxaliplatin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole... |
DB01211 | DB09039 | 609 | 1,670 | [
"DDInter393",
"DDInter629"
] | Clarithromycin | Eliglustat | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Major | 2 | [
[
[
609,
25,
1670
]
],
[
[
609,
62,
479
],
[
479,
23,
1670
]
],
[
[
609,
63,
211
],
[
211,
23,
1670
]
],
[
[
609,
25,
1135
],
[
1135,
... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donep... | Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tol... |
DB01035 | DB09272 | 1,401 | 412 | [
"DDInter1524",
"DDInter632"
] | Procainamide | Eluxadoline | A derivative of procaine with less CNS action. | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
1401,
24,
412
]
],
[
[
1401,
40,
824
],
[
824,
23,
412
]
],
[
[
1401,
63,
543
],
[
543,
24,
412
]
],
[
[
1401,
25,
1374
],
[
1374,
... | [
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Procainamide",
"{u} (Compound) resembles {v} (Compound)",
"Probenecid"
],
[
"Probenecid",
"{u} may cause a mi... | Procainamide (Compound) resembles Probenecid (Compound) and Probenecid may cause a minor interaction that can limit clinical effects when taken with Eluxadoline
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that co... |
DB00853 | DB14711 | 1,686 | 779 | [
"DDInter1762",
"DDInter1680"
] | Temozolomide | Smallpox (Vaccinia) Vaccine, Live | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
1686,
25,
779
]
],
[
[
1686,
64,
1064
],
[
1064,
25,
779
]
],
[
[
1686,
25,
1377
],
[
1377,
25,
779
]
],
[
[
1686,
63,
147
],
[
147,
... | [
[
[
"Temozolomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Temozolomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
... | Temozolomide may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Temozolomide may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to... |
DB01166 | DB12161 | 477 | 730 | [
"DDInter379",
"DDInter512"
] | Cilostazol | Deutetrabenazine | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives ... | Moderate | 1 | [
[
[
477,
24,
730
]
],
[
[
477,
62,
112
],
[
112,
23,
730
]
],
[
[
477,
63,
322
],
[
322,
24,
730
]
],
[
[
477,
24,
971
],
[
971,
24,... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Cilostazol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Deutetrabenazine
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin an... |
DB06043 | DB14783 | 1,644 | 287 | [
"DDInter1328",
"DDInter574"
] | Olaratumab | Diroximel fumarate | Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Stu... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
1644,
24,
287
]
],
[
[
1644,
63,
599
],
[
599,
24,
287
]
],
[
[
1644,
24,
270
],
[
270,
24,
287
]
],
[
[
1644,
25,
1510
],
[
1510,
... | [
[
[
"Olaratumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Olaratumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],... | Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab... |
DB00363 | DB01087 | 695 | 1,520 | [
"DDInter419",
"DDInter1520"
] | Clozapine | Primaquine | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Major | 2 | [
[
[
695,
25,
1520
]
],
[
[
695,
25,
1487
],
[
1487,
64,
1520
]
],
[
[
695,
6,
12523
],
[
12523,
45,
1520
]
],
[
[
695,
23,
112
],
[
112,
... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Primaquine"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine"... | Clozapine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Clozapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Primaquine (Compound)
Clozapine may cause a minor intera... |
DB00719 | DB04948 | 1,219 | 1,084 | [
"DDInter149",
"DDInter1083"
] | Azatadine | Lofexidine | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Moderate | 1 | [
[
[
1219,
24,
1084
]
],
[
[
1219,
24,
1617
],
[
1617,
1,
1084
]
],
[
[
1219,
63,
1020
],
[
1020,
1,
1084
]
],
[
[
1219,
24,
1311
],
[
1311... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
],
[
... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Apraclonidine and Apraclonidine (Compound) resembles Lofexidine (Compound)
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine (Compound) resembles Lofexidine (Compound... |
DB01611 | DB08901 | 1,487 | 1,468 | [
"DDInter893",
"DDInter1492"
] | Hydroxychloroquine | Ponatinib | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
1487,
24,
1468
]
],
[
[
1487,
25,
478
],
[
478,
24,
1468
]
],
[
[
1487,
6,
12523
],
[
12523,
45,
1468
]
],
[
[
1487,
21,
28852
],
[
28... | [
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
... | Hydroxychloroquine may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Hydroxychloroquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound)
Hydroxychloroquine (C... |
DB00539 | DB04946 | 11 | 924 | [
"DDInter1837",
"DDInter907"
] | Toremifene | Iloperidone | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Major | 2 | [
[
[
11,
25,
924
]
],
[
[
11,
25,
1664
],
[
1664,
1,
924
]
],
[
[
11,
25,
1425
],
[
1425,
25,
924
]
],
[
[
11,
25,
519
],
[
519,
40,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Risperidone"
],
[
"Risperidone",
"{u... | Toremifene may lead to a major life threatening interaction when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Toremifene may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Iloperi... |
DB01075 | DB01168 | 1,376 | 1,053 | [
"DDInter569",
"DDInter1526"
] | Diphenhydramine | Procarbazine | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
1376,
24,
1053
]
],
[
[
1376,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
1376,
40,
126
],
[
126,
23,
1053
]
],
[
[
1376,
63,
1000
],
[
10... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effec... | Diphenhydramine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Diphenhydramine (Compound) resembles Warfarin (Compound) and Warfarin may cause a minor interaction that can limit clinical effects when taken with Procarbazine
Diphenhydramine may cause a moderate i... |
DB08930 | DB11901 | 1,459 | 913 | [
"DDInter582",
"DDInter107"
] | Dolutegravir | Apalutamide | Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and ... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
1459,
25,
913
]
],
[
[
1459,
62,
600
],
[
600,
24,
913
]
],
[
[
1459,
23,
1320
],
[
1320,
63,
913
]
],
[
[
1459,
25,
286
],
[
286,
... | [
[
[
"Dolutegravir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Dolutegravir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluconazole"
],
[
"Flucon... | Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Elagolix and Elago... |
DB11581 | DB11988 | 1,456 | 270 | [
"DDInter1926",
"DDInter1321"
] | Venetoclax | Ocrelizumab | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process,. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lym... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
1456,
24,
270
]
],
[
[
1456,
64,
1491
],
[
1491,
24,
270
]
],
[
[
1456,
63,
951
],
[
951,
24,
270
]
],
[
[
1456,
25,
800
],
[
800,
... | [
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
[
"Midostau... | Venetoclax may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may c... |
DB01240 | DB05578 | 885 | 330 | [
"DDInter657",
"DDInter1566"
] | Epoprostenol | Ramucirumab | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Major | 2 | [
[
[
885,
25,
330
]
],
[
[
885,
24,
41
],
[
41,
63,
330
]
],
[
[
885,
24,
901
],
[
901,
24,
330
]
],
[
[
885,
63,
1100
],
[
1100,
24,... | [
[
[
"Epoprostenol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
]
],
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"... | Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Milnac... |
DB01136 | DB06663 | 772 | 1,154 | [
"DDInter305",
"DDInter1398"
] | Carvedilol | Pasireotide | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
772,
24,
1154
]
],
[
[
772,
63,
966
],
[
966,
40,
1154
]
],
[
[
772,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
772,
63,
959
],
[
959,
... | [
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
... | Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide (Compound) resembles Pasireotide (Compound)
Carvedilol (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Carvedilol may cause a moderate ... |
DB00060 | DB05528 | 912 | 1,070 | [
"DDInter947",
"DDInter1228"
] | Interferon beta-1a | Mipomersen | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Major | 2 | [
[
[
912,
25,
1070
]
],
[
[
912,
24,
292
],
[
292,
64,
1070
]
],
[
[
912,
24,
1512
],
[
1512,
25,
1070
]
],
[
[
912,
25,
593
],
[
593,
... | [
[
[
"Interferon beta-1a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
],
[
... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib may lead to a major life threatening interaction when taken with Mipomersen
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Dic... |
DB00176 | DB00736 | 529 | 660 | [
"DDInter770",
"DDInter676"
] | Fluvoxamine | Esomeprazole | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | Moderate | 1 | [
[
[
529,
24,
660
]
],
[
[
529,
24,
1215
],
[
1215,
40,
660
]
],
[
[
529,
24,
837
],
[
837,
1,
660
]
],
[
[
529,
6,
8374
],
[
8374,
4... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
... | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole (Compound) resembles Esomeprazole (Compound)
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole (Compound) resembles Esomeprazo... |
DB00372 | DB00964 | 999 | 1,617 | [
"DDInter1793",
"DDInter110"
] | Thiethylperazine | Apraclonidine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Apraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist. | Moderate | 1 | [
[
[
999,
24,
1617
]
],
[
[
999,
24,
1020
],
[
1020,
1,
1617
]
],
[
[
999,
24,
1084
],
[
1084,
40,
1617
]
],
[
[
999,
24,
530
],
[
530,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine (Compound) resembles Apraclonidine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine and Lofexidine (Compound) resembles Apracloni... |
DB00041 | DB01168 | 1,648 | 1,053 | [
"DDInter38",
"DDInter1526"
] | Aldesleukin | Procarbazine | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
1648,
24,
1053
]
],
[
[
1648,
23,
646
],
[
646,
23,
1053
]
],
[
[
1648,
23,
255
],
[
255,
62,
1053
]
],
[
[
1648,
24,
1000
],
[
1000,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cinoxacin"
],
[
... | Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin and Cinoxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin and Delaflox... |
DB00073 | DB01030 | 1,394 | 869 | [
"DDInter1608",
"DDInter1835"
] | Rituximab | Topotecan | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences... | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Moderate | 1 | [
[
[
1394,
24,
869
]
],
[
[
1394,
24,
1270
],
[
1270,
63,
869
]
],
[
[
1394,
63,
1184
],
[
1184,
24,
869
]
],
[
[
1394,
24,
599
],
[
599,
... | [
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein de... | Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Rituximab may cause a moderate interaction that could exac... |
DB00176 | DB06282 | 529 | 516 | [
"DDInter770",
"DDInter1053"
] | Fluvoxamine | Levocetirizine | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
529,
24,
516
]
],
[
[
529,
25,
1031
],
[
1031,
23,
516
]
],
[
[
529,
24,
701
],
[
701,
24,
516
]
],
[
[
529,
24,
407
],
[
407,
6... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Fluvoxamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Theophylline"
],
[
"Th... | Fluvoxamine may lead to a major life threatening interaction when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Levocetirizine
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine ma... |
DB01208 | DB04868 | 945 | 478 | [
"DDInter1705",
"DDInter1293"
] | Sparfloxacin | Nilotinib | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
945,
25,
478
]
],
[
[
945,
6,
4973
],
[
4973,
45,
478
]
],
[
[
945,
7,
10861
],
[
10861,
46,
478
]
],
[
[
945,
18,
2183
],
[
2183,
... | [
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Sparfloxacin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Niloti... | Sparfloxacin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nilotinib (Compound)
Sparfloxacin (Compound) upregulates KCTD5 (Gene) and KCTD5 (Gene) is upregulated by Nilotinib (Compound)
Sparfloxacin (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Nilotinib (Compound)
Sparfloxacin ... |
DB01072 | DB09038 | 915 | 1,450 | [
"DDInter129",
"DDInter636"
] | Atazanavir | Empagliflozin | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
915,
24,
1450
]
],
[
[
915,
24,
659
],
[
659,
63,
1450
]
],
[
[
915,
64,
1486
],
[
1486,
24,
1450
]
],
[
[
915,
63,
1179
],
[
1179,
... | [
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[... | Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Atazanavir may lead to a major life threatening interaction when taken with Methylprednisolone and Methylpred... |
DB00284 | DB01064 | 1,647 | 1,148 | [
"DDInter11",
"DDInter987"
] | Acarbose | Isoprenaline | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Moderate | 1 | [
[
[
1647,
24,
1148
]
],
[
[
1647,
24,
1636
],
[
1636,
24,
1148
]
],
[
[
1647,
21,
28722
],
[
28722,
60,
1148
]
],
[
[
1647,
24,
251
],
[
2... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
],
[
... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Acarbose (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Isoprenaline (Compou... |
DB00939 | DB04932 | 1,338 | 1,564 | [
"DDInter1135",
"DDInter491"
] | Meclofenamic acid | Defibrotide | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Da... | Moderate | 1 | [
[
[
1338,
24,
1564
]
],
[
[
1338,
24,
1039
],
[
1039,
24,
1564
]
],
[
[
1338,
24,
738
],
[
738,
63,
1564
]
],
[
[
1338,
63,
121
],
[
121,
... | [
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluram... | Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken w... |
DB01169 | DB11915 | 57 | 1,293 | [
"DDInter120",
"DDInter1909"
] | Arsenic trioxide | Valbenazine | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Major | 2 | [
[
[
57,
25,
1293
]
],
[
[
57,
62,
112
],
[
112,
23,
1293
]
],
[
[
57,
64,
521
],
[
521,
24,
1293
]
],
[
[
57,
25,
392
],
[
392,
24,
... | [
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valbenazine"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Valbenazine
Arsenic trioxide may lead to a major life threatening interaction when taken with Goserelin and Goserel... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.